Discover
oral etanercept (OPRX-106) / ProtalixOPRX-106 clinical trial estimate: Data from P2 trial (NCT02768974) for ulcerative colitis in H2 2019 (Jefferies) - Sep 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67787343; Page no: 1; REPORT TITLE: "Protalix Biotherapeutics Inc Go-ahead for expedited US path; PRX-102 filing expected in 1Q20”; AUTHOR: Welford, Peter, et al; DATE: 08/08/2019PTG-200 / Protagonist Therapeutics, J&JPTG-200: Data from P1 trial in healthy volunteers in 2019 (H.C. Wainwright Global Life Sciences Conference 2019, Protagonist Therapeutics) - Sep 11, 2019 [Screenshot]Remicade (infliximab) / Mitsubishi Tanabe, J&JRemicade pricing: $28,906/year (Infinata) - Sep 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 67557275; Page no: 8; REPORT TITLE: "UCB S.A. - Company report”; AUTHOR: Infinata, et al; DATE: 09/03/2019Otezla (apremilast) / AmgenOtezla sales projection: $2.1B in 2020 (CFRA) - Sep 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67896905; Page no: 5; REPORT TITLE: "Amgen Inc.”; AUTHOR: Huang, Kevin, et al; DATE: 08/31/2019Rinvoq (upadacitinib) / AbbVieRinvoq sales projection: $236M for ulcerative colitis in 2026 and $690M for ulcerative colitis and Crohn’s disease in 2030 (Infinata) - Sep 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67557855; Page no: 12; REPORT TITLE: "AbbVie Inc. - Company report”; AUTHOR: Infinata, et al; DATE: 09/03/2019Entyvio (vedolizumab) / TakedaEntyvio sales projection: $4,425M by 2025 (GlobalData) - Sep 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 67577535; Page no: 64; REPORT TITLE: "Takeda Pharmaceutical Co Ltd (4502) - Financial and strategic SWOT analysis review”; AUTHOR: Globaldata, et al; DATE: 09/05/2019Stelara (ustekinumab) / J&JSerum Institute unveils ₹4,000-cr plant in Pune (The Hindu Business Line) - Sep 9, 2019 - "Union Health Minister...on Monday inaugurated Serum Institute of India’s (SII) new plant with an investment of ₹4,000 crore at Manjri in Pune. The new unit, which will commence operations from November...The unit is built in compliance with the US and European vaccine manufacturing regulations....It will maximise the production of...monoclonal antibodies like...Ustekinumab (Stelara®)."Tremfya (guselkumab) / J&JTremfya sales projection: $3B in 2024 (MainFirst Bank AG) - Sep 16, 2019 - A subscription to Thomson ONE is required to gain full access to report 67932139; Page no: 30; REPORT TITLE: "MainFirst AG- Initiating coverage: MainFirst: Morphosys AG (OPF / EUR 140): On the cusp of transformation supported by a fat wallet”; AUTHOR: Wieprecht, Marcus, et al; DATE: 09/08/2019Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi WW sales projection: $300M in FY2019 and $800M in FY2020 (Piper Jaffray) - Sep 9, 2019 - A subscription to Thomson ONE is required to gain full access to report 67909429; Page no: 1; REPORT TITLE: "Abbvie Inc - Skyrizi En Fuego - New derm survey indicates Q219 was no fluke”; AUTHOR: Raymond, Christopher, et al; DATE: 09/04/2019
